AU2019337018B2 - Method of producing tetracyclic compound - Google Patents

Method of producing tetracyclic compound Download PDF

Info

Publication number
AU2019337018B2
AU2019337018B2 AU2019337018A AU2019337018A AU2019337018B2 AU 2019337018 B2 AU2019337018 B2 AU 2019337018B2 AU 2019337018 A AU2019337018 A AU 2019337018A AU 2019337018 A AU2019337018 A AU 2019337018A AU 2019337018 B2 AU2019337018 B2 AU 2019337018B2
Authority
AU
Australia
Prior art keywords
group
formula
compound
compound represented
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019337018A
Other languages
English (en)
Other versions
AU2019337018A1 (en
Inventor
Hiroshi Fukuda
Naoto Hama
Akira Kawase
Hiroki SERIZAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2019337018A1 publication Critical patent/AU2019337018A1/en
Application granted granted Critical
Publication of AU2019337018B2 publication Critical patent/AU2019337018B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019337018A 2018-09-04 2019-09-03 Method of producing tetracyclic compound Active AU2019337018B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
JP2018-165313 2018-09-04
PCT/JP2019/034543 WO2020050241A1 (ja) 2018-09-04 2019-09-03 ４環性化合物の製造方法

Publications (2)

Publication Number Publication Date
AU2019337018A1 AU2019337018A1 (en) 2021-03-18
AU2019337018B2 true AU2019337018B2 (en) 2024-03-07

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019337018A Active AU2019337018B2 (en) 2018-09-04 2019-09-03 Method of producing tetracyclic compound

Country Status (18)

Country Link
US (1) US11939322B2 (https=)
EP (1) EP3848361B1 (https=)
JP (1) JP7167171B2 (https=)
KR (1) KR102635225B1 (https=)
CN (1) CN112585126B (https=)
AR (1) AR116113A1 (https=)
AU (1) AU2019337018B2 (https=)
BR (1) BR112021001145A2 (https=)
CA (1) CA3107270A1 (https=)
ES (1) ES3010145T3 (https=)
HR (1) HRP20250284T1 (https=)
HU (1) HUE070227T2 (https=)
IL (1) IL281079B2 (https=)
MX (1) MX2021002311A (https=)
PL (1) PL3848361T3 (https=)
SG (1) SG11202100983XA (https=)
TW (1) TWI825163B (https=)
WO (1) WO2020050241A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4285907A4 (en) 2021-01-29 2024-11-13 Chugai Seiyaku Kabushiki Kaisha Drug composition for treating pediatric cancers
CN117024410A (zh) * 2023-08-15 2023-11-10 上海药坦药物研究开发有限公司 一种艾乐替尼中间体及其制备方法
WO2025067412A1 (zh) * 2023-09-28 2025-04-03 重庆博腾制药科技股份有限公司 一种抗肿瘤药物中间体的制备方法
CN120081779A (zh) * 2025-02-19 2025-06-03 江苏天士力帝益药业有限公司 一种阿来替尼杂质01a及其控制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441753A1 (en) * 2009-06-10 2012-04-18 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (https=) 1970-02-17 1975-03-19
JPS4918630B1 (https=) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
EA001450B1 (ru) 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
ES2292262T3 (es) * 1998-12-24 2008-03-01 Astellas Pharma Inc. Compuestos de imidazol y su uso medicinal.
EP1178988B1 (en) 1999-05-14 2007-02-28 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
JP2007513890A (ja) 2003-12-12 2007-05-31 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
MXPA06014066A (es) * 2004-06-02 2007-02-15 Pharmacyclics Inc Inhibicion de factor viia.
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
RU2008122547A (ru) 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
MX2011011661A (es) 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
WO2015193309A1 (en) 2014-06-18 2015-12-23 F. Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) * 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441753A1 (en) * 2009-06-10 2012-04-18 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound

Also Published As

Publication number Publication date
CA3107270A1 (en) 2020-03-12
IL281079B1 (en) 2024-08-01
HUE070227T2 (hu) 2025-05-28
US20220372025A1 (en) 2022-11-24
WO2020050241A1 (ja) 2020-03-12
CN112585126B (zh) 2024-05-07
HRP20250284T1 (hr) 2025-04-25
AR116113A1 (es) 2021-03-31
EP3848361A1 (en) 2021-07-14
EP3848361C0 (en) 2025-01-22
EP3848361A4 (en) 2022-06-15
EP3848361B1 (en) 2025-01-22
TW202024050A (zh) 2020-07-01
KR20210053890A (ko) 2021-05-12
CN112585126A (zh) 2021-03-30
JPWO2020050241A1 (ja) 2021-08-30
JP7167171B2 (ja) 2022-11-08
IL281079B2 (en) 2024-12-01
PL3848361T3 (pl) 2025-07-07
AU2019337018A1 (en) 2021-03-18
SG11202100983XA (en) 2021-03-30
ES3010145T3 (en) 2025-04-01
MX2021002311A (es) 2021-04-28
BR112021001145A2 (pt) 2021-04-20
IL281079A (en) 2021-04-29
TWI825163B (zh) 2023-12-11
US11939322B2 (en) 2024-03-26
KR102635225B1 (ko) 2024-02-07

Similar Documents

Publication Publication Date Title
AU2019337018B2 (en) Method of producing tetracyclic compound
JP6392436B2 (ja) 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
AU2015226679B2 (en) Piperidine derivatives as orexin receptor antagonist
RS64654B1 (sr) Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
CN110612291B (zh) 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
US20090221828A1 (en) Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives
WO2017109524A1 (en) Method and intermediate for the production of baricitinib
JP6030644B2 (ja) 置換されたフェニル化合物
HK40051429A (en) Method of producing tetracyclic compound
CN120718016A (zh) 一种kras抑制剂型抗肿瘤药mrtx849合成工艺
CN100383144C (zh) 一种奥氮平的中间体及其制备与应用
HK40051429B (zh) 四环化合物的制备方法
TW202610622A (zh) 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羥甲基)-5-(1-羥基-1-甲基-乙基)-1-甲基-3,4-二氫-1h-異喹啉-2-基]乙酮一水合物之製造方法
TW201540713A (zh) 作為食慾激素受體拮抗劑的呱啶衍生物
NO330342B1 (no) Ny fremgangsmate for fremstilling av imidazolylforbindelser
NZ724215B2 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines